8-K: Biofrontera Inc. Announces Third Quarter and Nine-Month 2024 Financial Results, Cites Hurricane Impact

Biofrontera Inc. reported a 1.5% revenue increase for Q3 2024, which would have been 19% without shipment delays caused by Hurricane Milton, and a 5.6% increase for the first nine months, which would have been 12% without the hurricane impact.

Summary

• Biofrontera Inc. announced its financial results for the third quarter and the first nine months of 2024, ending September 30, 2024.
• Third-quarter revenue reached $9.0 million, a 1.5% increase compared to the same period in 2023.
• However, this growth was significantly impacted by Hurricane Milton, which delayed shipments of Ameluz, reducing the potential revenue growth from 19% to 1.5%.
• The delayed shipments amounted to 4,640 tubes of Ameluz, representing approximately $1.5 million in revenue, which will be recognized in Q4.
• For the first nine months of 2024, total revenue was $24.8 million, a 5.6% increase year-over-year, which would have been 12% without the hurricane impact.
• The company's cash and cash equivalents stood at $2.9 million as of September 30, 2024, compared to $1.3 million at the end of 2023.
• The company saw a 14% reduction in selling, general, and administrative expenses for the first nine months of 2024 compared to 2023.
• The RhodoLED XL launch has been successful with 39 units installed since late June 2024, and 66 BF-RhodoLED lamps were installed in the first three quarters of 2024.
• The FDA approved an increase in the maximum dosage of Ameluz from one to three tubes per treatment on October 4, 2024.
• Preliminary results from a Phase 3 sBCC study showed highly statistically significant results with Ameluz-PDT achieving 75.9% histological clearance compared to 19% with placebo.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful product launches, FDA approval, and positive clinical trial results, but is tempered by the negative impact of the hurricane on revenue and the ongoing losses.

Positives

• The company experienced a 1.5% increase in revenue for the third quarter of 2024, and a 5.6% increase for the first nine months of 2024.
• The company has successfully reduced selling, general, and administrative expenses by 14% in the first nine months of 2024.
• The launch of RhodoLED XL has been successful with 39 units installed since late June 2024.
• The FDA approved an increase in the maximum dosage of Ameluz from one to three tubes per treatment.
• The Phase 3 sBCC study showed highly statistically significant results for Ameluz-PDT.
• Cash and cash equivalents increased significantly from $1.3 million to $2.9 million.

Negatives

• Hurricane Milton significantly impacted third-quarter revenue, delaying shipments and reducing growth.
• The company experienced a net loss of $5.7 million for the third quarter of 2024.
• Adjusted EBITDA for the third quarter of 2024 was negative $4.6 million.
• The company's operating expenses were $14.0 million for the third quarter of 2024.
• The company's net loss for the first nine months of 2024 was $16.363 million.

Risks

• The company's revenue is heavily reliant on sales of licensed products.
• Competition from other pharmaceutical and medical device companies poses a risk.
• The company's ability to achieve and sustain profitability is uncertain.
• The company's ability to obtain additional financing as needed is a risk.
• The company is subject to risks related to manufacturing and supply of licensed products.
• The company is involved in legal proceedings with a competitor.

Future Outlook

The company expects to submit an FDA filing for the approval of Ameluz for the treatment of sBCC in the first half of 2025, with anticipated approval in early 2026. They are also implementing a comprehensive update to their commercial strategy to drive significant sales growth.

Management Comments

• Hermann Luebbert, CEO, stated that while pleased with the third quarter results, they faced challenges from Hurricane Milton that impacted their business.
• He noted that the hurricane delayed the shipment of 4,640 tubes of Ameluz, representing approximately $1.5 million in revenue.
• He also mentioned the positive uptake of their products throughout the United States, illustrated by the number of lamps sold to dermatology offices.
• He highlighted the seamless transfer of clinical trial activities from Biofrontera AG to Biofrontera Inc.
• He concluded that the extended approval for Ameluz dosage will drive significant sales growth in the coming years.

Industry Context

This announcement comes as Biofrontera continues to expand its presence in the photodynamic therapy market, focusing on dermatological conditions. The company's progress in clinical trials and FDA approvals are key to its competitive positioning against other pharmaceutical and medical device companies in the dermatology space.

Comparison to Industry Standards

• Biofrontera's revenue growth of 1.5% in Q3 2024 is below the average growth rate for the pharmaceutical industry, which is typically in the mid-single to low-double digits, however, the company has stated that this was due to a one-off event.
• The company's adjusted EBITDA of negative $4.6 million for Q3 2024 indicates that the company is not yet profitable, which is not uncommon for companies in the development stage, but is worse than some of its peers.
• The successful launch of RhodoLED XL and the FDA approval for increased Ameluz dosage are positive developments that could improve the company's competitive position.
• The 75.9% histological clearance rate in the Phase 3 sBCC study is a strong result, potentially exceeding the efficacy of some existing treatments.
• Companies like Photocure ASA, which also focuses on photodynamic therapy, have shown similar growth rates in certain periods, but Biofrontera's results are impacted by the hurricane.
• Compared to companies like Galderma, which has a broader portfolio of dermatological products, Biofrontera is more focused on PDT, making direct comparisons challenging.

Legal Proceedings

• The company is involved in legal proceedings with a competitor at the International Trade Commission (ITC) and the US District Court for the District of Massachusetts.

Stakeholder Impact

• Shareholders may be concerned about the impact of the hurricane on revenue and the ongoing losses.
• Employees may be affected by the company's cost-cutting measures.
• Customers may benefit from the increased dosage of Ameluz and the successful launch of new products.
• Suppliers may be impacted by changes in the company's supply chain.
• Creditors may be concerned about the company's financial performance.

Next Steps

• The company will ship the delayed Ameluz tubes in Q4.
• The company will submit an FDA filing for the approval of Ameluz for the treatment of sBCC in the first half of 2025.
• The company will implement a comprehensive update to its commercial strategy to drive sales growth.
• The company will continue to progress its clinical trials.

Key Dates

Keywords

Biofrontera, Ameluz, RhodoLED, Photodynamic Therapy, PDT, Actinic Keratosis, sBCC, Financial Results, Revenue, EBITDA, FDA Approval, Clinical Trials